Pharmaceutical company GlaxoSmithKline and Vir Biotechnology have reached their primary end point with a phase III clinical study of intramuscular administration of sotrovimab.
The study showed that intramuscular administration is not inferior to intravenous administration for early treatment of COVID-19 in high-risk adults and adolescents. The companies noted that the study was conducted at the height of the delta variable prevalence in Florida.
“We designed sotrovimab to withstand the variants we expected, and this data shows that sotrovimab, given intravenously or intramuscularly, will prove valuable in the fight against COVID-19 once approved,” Vir CEO George Scangos said.
Shares of UK-listed GlaxoSmithKline rose 0.31 percent at times to 15.94 pounds, while shares of Fair rose 1.94 percent in US trading to $32.42.
London (Dow Jones)
“Total coffee aficionado. Travel buff. Music ninja. Bacon nerd. Beeraholic.”
More Stories
GenAI in everyday work – Top management is moving forward with AI, employees are hesitant » Leadersnet
Foreign Exchange: Euro rises against the dollar
Lufthansa Group: Austrian Airlines, the Boeing 737 MAX and the cargo problem